Allergic Rhinitis Management Guidelines
The Libyan Rhinology Society has published updated consensus guidelines for the diagnosis and management of allergic rhinitis, with a dedicated focus on pediatric presentations in the Libyan clinical context.
Background
Allergic rhinitis represents one of the most prevalent chronic conditions encountered in ENT practice across Libya, with an estimated prevalence of 15–20% in the general population and a notably higher incidence among children under 12. Despite its high prevalence, significant variability in diagnostic approaches and treatment protocols has been observed across different health facilities nationwide.
In response, the LRS Scientific Committee convened a panel of specialist rhinologists, pediatric otolaryngologists, and allergists to develop a unified national framework aligned with international ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines, adapted for local clinical conditions and available therapeutics.
Key Recommendations
1. Diagnosis
A structured clinical history combined with skin prick testing remains the diagnostic gold standard. Nasal endoscopy is recommended for all moderate-to-severe presentations to exclude concurrent structural pathology.
2. First-Line Treatment
Intranasal corticosteroids (INS) are confirmed as the most effective first-line pharmacological treatment for persistent allergic rhinitis in both adults and children above 2 years of age. Oral antihistamines are recommended as adjunct therapy for intermittent symptoms.
3. Pediatric Considerations
Allergen avoidance education and environmental control measures should be prioritized in pediatric management. Allergen immunotherapy (AIT) may be considered in children aged 5 and above with confirmed sensitization and inadequate response to pharmacotherapy.
4. Follow-Up Protocol
A structured 6-week follow-up is recommended after initiation of treatment to assess response and tolerability. Annual review is advised for all patients on long-term intranasal corticosteroids to monitor for local adverse effects.
Availability
The full guidelines document is available exclusively to LRS members through the member portal. A condensed clinical reference card suitable for outpatient use will be distributed at the upcoming LRS Annual Congress.
ENT departments and health facilities wishing to adopt these guidelines as a local standard of care are encouraged to contact the LRS Scientific Affairs office for implementation support.
Access the Full Guidelines
LRS members can access the complete guidelines document through the member portal.